These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 18483253

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.
    Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D, D'Orazi G.
    Exp Cell Res; 2009 Jan 01; 315(1):67-75. PubMed ID: 18996371
    [Abstract] [Full Text] [Related]

  • 3. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
    Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, Blandino G, Mottolese M, Falcioni R.
    Cancer Res; 2009 Jul 15; 69(14):5978-86. PubMed ID: 19567674
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R, Nardinocchi L, Pistritto G, D'Orazi G.
    Gynecol Oncol; 2008 Jun 15; 109(3):403-10. PubMed ID: 18395248
    [Abstract] [Full Text] [Related]

  • 5. HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA.
    Nardinocchi L, Puca R, Sacchi A, D'Orazi G.
    Biochem Biophys Res Commun; 2007 Sep 14; 361(1):249-55. PubMed ID: 17658469
    [Abstract] [Full Text] [Related]

  • 6. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation.
    Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W, Zhou HM, Cheung PY, Wu Z, Ye Z, Li P, Han J, Lin SC.
    EMBO J; 2004 Nov 24; 23(23):4583-94. PubMed ID: 15526030
    [Abstract] [Full Text] [Related]

  • 7. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
    Di Stefano V, Soddu S, Sacchi A, D'Orazi G.
    Oncogene; 2005 Aug 18; 24(35):5431-42. PubMed ID: 15897882
    [Abstract] [Full Text] [Related]

  • 8. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
    Puca R, Nardinocchi L, Givol D, D'Orazi G.
    Oncogene; 2010 Aug 05; 29(31):4378-87. PubMed ID: 20514025
    [Abstract] [Full Text] [Related]

  • 9. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.
    Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S, Aikawa Y, Kimura A, Kitabayashi I.
    Oncogene; 2007 Nov 08; 26(51):7231-9. PubMed ID: 17533375
    [Abstract] [Full Text] [Related]

  • 10. Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression.
    Möller A, Sirma H, Hofmann TG, Staege H, Gresko E, Lüdi KS, Klimczak E, Dröge W, Will H, Schmitz ML.
    Oncogene; 2003 Nov 27; 22(54):8731-7. PubMed ID: 14647468
    [Abstract] [Full Text] [Related]

  • 11. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
    Szepeshazi K, Schally AV, Halmos G, Armatis P, Hebert F, Sun B, Feil A, Kiaris H, Nagy A.
    Cancer Res; 2002 Feb 01; 62(3):781-8. PubMed ID: 11830533
    [Abstract] [Full Text] [Related]

  • 12. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
    Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH.
    Cancer Res; 2001 Jun 15; 61(12):4910-5. PubMed ID: 11406570
    [Abstract] [Full Text] [Related]

  • 13. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C, Claudio PP, Luca AD, Cuccurese M, Howard CM, D'Esposito M, Paggi MG, Sala DL, Azzoni L, Halazonetis TD, Giordano A, Maraldi NM.
    Oncogene; 2000 Oct 19; 19(44):5098-105. PubMed ID: 11042698
    [Abstract] [Full Text] [Related]

  • 14. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model.
    Nambiar PR, Giardina C, Guda K, Aizu W, Raja R, Rosenberg DW.
    Cancer Res; 2002 Jul 01; 62(13):3667-74. PubMed ID: 12097273
    [Abstract] [Full Text] [Related]

  • 15. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
    D'Orazi G, Garufi A, Cirone M.
    IUBMB Life; 2020 Aug 01; 72(8):1634-1639. PubMed ID: 32593231
    [Abstract] [Full Text] [Related]

  • 16. FHL2 mediates p53-induced transcriptional activation through a direct association with HIPK2.
    Lee SW, Kim EJ, Um SJ.
    Biochem Biophys Res Commun; 2006 Jan 27; 339(4):1056-62. PubMed ID: 16343438
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4.
    Yamada D, Pérez-Torrado R, Filion G, Caly M, Jammart B, Devignot V, Sasai N, Ravassard P, Mallet J, Sastre-Garau X, Schmitz ML, Defossez PA.
    Oncogene; 2009 Jul 09; 28(27):2535-44. PubMed ID: 19448668
    [Abstract] [Full Text] [Related]

  • 19. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.
    D'Orazi G, Sciulli MG, Di Stefano V, Riccioni S, Frattini M, Falcioni R, Bertario L, Sacchi A, Patrignani P.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):735-41. PubMed ID: 16467083
    [Abstract] [Full Text] [Related]

  • 20. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein.
    Vinyals A, Peinado MA, Gonzalez-Garrigues M, Monzó M, Bonfil RD, Fabra A.
    Gene Ther; 1999 Jan 01; 6(1):22-33. PubMed ID: 10341872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.